Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours

[1]  T. Tsuruo,et al.  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[2]  M. Ducreux,et al.  Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[4]  Z Topcu,et al.  DNA topoisomerases as targets for anticancer drugs , 2001, Journal of clinical pharmacy and therapeutics.

[5]  J Verweij,et al.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  M. Kurihara,et al.  Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer , 2001, Cancer Chemotherapy and Pharmacology.

[7]  U. Vanhoefer,et al.  Irinotecan in the treatment of colorectal cancer: clinical overview. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Nair,et al.  Evaluation of topotecan and etoposide for non‐hodgkin lymphoma , 2001, Cancer.

[9]  J P Pignon,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[10]  L. Liu,et al.  Tumor cell death induced by topoisomerase-targeting drugs. , 2001, Annual review of pharmacology and toxicology.

[11]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[12]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[13]  J. Sloan,et al.  Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Y. Ohashi,et al.  Phase II Study of Irinotecan and Cisplatin as First-Line Chemotherapy in Advanced or Recurrent Cervical Cancer , 2000, Oncology.

[15]  J. Verweij,et al.  Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Verweij,et al.  Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Saotome,et al.  Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  K. Goa,et al.  Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. , 1999, Drugs & aging.

[19]  G. Schwartz,et al.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Shibahara,et al.  A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. , 1999, Japanese journal of clinical oncology.

[21]  F. Goldwasser,et al.  Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Hyodo,et al.  Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Kemeny,et al.  Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Fukuoka,et al.  Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Kunikane,et al.  A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte‐colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma , 1998, Cancer.

[26]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[27]  M. Fukuoka,et al.  Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Hibino,et al.  Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer , 1998, Cancer Chemotherapy and Pharmacology.

[29]  B. Teicher,et al.  Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo , 1998, Cancer Chemotherapy and Pharmacology.

[30]  Y. Nakanishi,et al.  Effect of CPT-11 in combination with other anticancer agents in lung cancer cells , 1997, Anti-cancer drugs.

[31]  K. Mori,et al.  A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer , 1997, Cancer Chemotherapy and Pharmacology.

[32]  N. Saijo,et al.  Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Kaye,et al.  Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? , 1997, British Journal of Cancer.

[34]  A. C. Dubbelman,et al.  Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. , 1997, British Journal of Cancer.

[35]  H. Ohmatsu,et al.  Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. , 1997, British Journal of Cancer.

[36]  T. Hickish,et al.  Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  N. Kemeny,et al.  Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Saijo,et al.  Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. , 1996, Cancer research.

[39]  M. Fukuoka,et al.  Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Hickish,et al.  A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[42]  N. Habboubi,et al.  Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. , 1993, Cancer treatment reviews.

[43]  R. Kim,et al.  Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice , 1992, International journal of cancer.

[44]  Y. Miura,et al.  Effects of CPT‐11 in combination with other anti‐cancer agents in culture , 1992, International journal of cancer.

[45]  Y. Pommier,et al.  Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. , 1991, Cancer research.

[46]  S. Kaufmann,et al.  Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. , 1991, Cancer research.

[47]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[48]  H. Takano,et al.  Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. , 1990, Cancer research.